F2RL1 and migraine disorder: Taken together, our present findings support the idea that PAR2 activation can increase sensitivity to NO leading to a pain phenotype similar to that observed in migraine patients and further support that antagonism of PAR2 may be a novel therapeutic approach for migraine.